ABSTRACT
Background Familial hypercholesterolemia (FH) is a prevalent genetic disorder with global implications for severe cardiovascular diseases. Amid ongoing advancements in genetic disease screening and treatment, the economic evaluation of FH is increasingly vital. Despite numerous studies, international disparities persist, necessitating a comprehensive analysis of the economic assessments of FH screening to provide valuable insights. This study aims to globally examine economic assessments of FH, synthesize evidence, and present economic insights into the impact of FH screening on population equity.
Methods Systematic literature analysis was used to systematically evaluate 19 FH screening economic evaluation studies and synthesize the evidence. Meta-analysis was used to comprehensively explore the total cost-effectiveness and total net health benefit of different FH screening methods. The aggregate Distributional Cost-Effectiveness Analysis (DCEA) was utilized to assess the impact of FH screening on population equity.
Results The study results reveal significant differences in the economic evaluations of FH across different countries, and we provide detailed descriptions of unique characteristics. The comprehensive results of cost-effectiveness analysis indicate that FH screening is cost-effective in the majority of countries. The meta-analysis synthesizes the economic impacts of Cascade Screening and Universal Screening across various health outcomes. Additionally, our aggregate Distributional Cost-Effectiveness Analysis (DCEA) suggests that FH screening strategies have the potential to alleviate health inequalities.
Conclusion This study provides a global perspective on FH economic evaluation. Despite international differences, findings suggest that, in the majority of cases, FH screening is cost-effective, improving health equity and overall population health. The study offers a positive outlook for future health decisions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not receive support from any organization for the submitted work. No funding was received to assist with the preparation of this manuscript. No funding was received for conducting this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of interest: None.
format of the main text; format of tables.
Data Availability
All data produced in the present work are contained in the manuscript
